Drug intelligence / Profile preview

Drotax Drops

Development stage: Phase 4
Lead developer: Osvel Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Drotax Drops** is an oral fixed-dose gastrointestinal product marketed by Osvel Pharma. The product listing identifies the active ingredients as dicyclomine hydrochloride 10 mg and activated dimethicone 40 mg. Dicyclomine is an antimuscarinic antispasmodic that reduces gastrointestinal smooth-muscle spasm, while activated dimethicone, also called simethicone, is an anti-foaming agent that coalesces intestinal gas bubbles to reduce gas-related bloating and discomfort. ([osvelpharma.in](https://www.osvelpharma.in/product/dicyclomine-hydrochloride-10-mg-activated-dimethicone-40-mg/))

Brand names: Drotax Drops
Other names: dicyclomine hydrochloride + activated dimethiconedicyclomine + simethicone

Targets

LTCC (Voltage-gated calcium channel (L-type))PDE4 (Phosphodiesterase 4A1)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Drotax Drops.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Drotax Drops.